• Stifel Nicolaus analyst Rick Wise set a $75.00 price target for Boston Scientific, suggesting a 46.86% upside from its $51.07 trading price at the time.
• Despite a positive analyst outlook, Boston Scientific has faced significant stock declines, including a 44.80% drop over the past year and a 39.50% year-to-date decrease.

Boston Scientific (NYSE: BSX) is a global company that develops and sells medical devices. These devices are used in many medical fields, helping doctors treat a wide range of conditions. Boston Scientific operates in a competitive industry with other major medical technology firms, all working to create innovative healthcare solutions.

On May 27, 2026, Stifel Nicolaus analyst Rick Wise adjusted the price target for Boston Scientific to $75.00. At that time, the stock was trading at $51.07 per share. This new target suggests a potential increase of about 46.86% from its price when the report was released, showing the analyst’s confidence in its future.

This analyst update comes as Boston Scientific faces significant price challenges. The company’s stock has declined 44.80% over the past year and has dropped 39.50% since the start of the year. On one recent day, the stock fell 11.92% to $50.77, touching a new 52-week low of $50.58 during the session.

Wall Street analysts are optimistic, as highlighted by Zacks. The stock has an average brokerage recommendation of 1.32, which is close to a Strong Buy. Out of 31 firms covering the stock, 24 rate Boston Scientific a Strong Buy, and an additional four give it a Buy rating.